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Abstract. Inflammatory bowel disease (IBD) is a chronic and 
progressive inflammatory condition of the gastrointestinal 
tract. Although the causative events that lead to the onset of 
IBD are yet to be fully elucidated, deregulation of immune and 
inflammatory mechanisms are hypothesized to significantly 
contribute to this disorder. Since the onset of IBD is often during 
infancy, in the present study, the serum values of a large panel 
of cytokines and chemokines in pediatric patients (<18 years; 
n=26) were compared with age‑matched controls (n=37). 
While elevations in the serum level of several proinflamma-
tory and immune regulating cytokines were confirmed, such 
as interleukin (IL)‑1β, IL‑5, IL‑7, interferon (IFN)‑γ‑inducible 
protein‑10, IL-16, cutaneous T‑cell‑attracting chemokine, 
leukemia inhibitory factor, monokine induced by γ‑IFN, 
IFN‑α2 and IFN‑γ, notably decreased levels of IL‑2, IL‑17 
and macrophage inhibitory protein‑1β were also observed. 
Therefore, while a number of proinflammatory cytokines 
exhibit increased levels in IBD patients, pediatric IBD patients 
may also exhibit certain aspects of a reduced immunological 
response.
Introduction
Inflammatory bowel disease (IBD) is an inflammatory condi-
tion of the gastrointestinal tract that comprises two forms: 
Ulcerative colitis and Crohn's disease. IBD is characterized by 
chronic inflammation, remitting and relapsing episodes, and 
a progressive course at diagnosis (1). Four aspects are known 
to be involved in the etiopathogenesis of IBD, including the 
external environment, the genetic signature of the patient, the 
microbiota and the immune system (2). Specific pathogenic 
agents or the physiological microbial flora provide antigenic 
stimulation of cell‑mediated immune responses in geneti-
cally susceptible individuals, while the presence of dysbiosis 
or impaired gastrointestinal mucosal barriers, due to genetic 
factors or environmentally‑induced injury, represent risk 
factors for the development of an inappropriate immune 
response (3,4).
Innate and adaptive immunity are known to play a crucial 
role in triggering and maintaining inflammatory events in 
IBD (5,6). Furthermore, an important underlying mechanism 
is the production and release of cytokines and chemokines, 
which are able to drive inflammatory events at a local and 
systemic level. In a recent study, the normal production of 
cytokines and chemokines was shown to vary consistently 
with the individual growth of healthy subjects and the physi-
ological sharpening of the immune system (7). The diagnosis 
of IBD is particularly challenging in patients of a pediatric 
age, since presenting symptoms can vary widely and may only 
consist of subtle extraintestinal manifestations. Often children 
present IBD‑like phenotypes and symptoms; however, they do 
not suffer from IBD. A long period of unmanaged symptoms 
can significantly impact on growth; thus, early treatments 
are essential to preserve the long‑term quality of life of 
patients (8,9).
Although non‑invasive tests for IBD already exist, including 
antibody tests, imaging‑based screens and fecal biomarkers (10), 
a comprehensive comparison of the serum levels of cyto-
kines and chemokines in pediatric IBD patients compared 
with normal age‑matched controls has yet to be performed. 
Therefore, the aim of the present study was to assess a large 
panel (n=48) of inflammatory cytokines and chemokines in 
pediatric IBD patients, and compare the results with the same 
panel in age‑matched healthy controls.
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Subjects and methods
Patients and normal controls. The independent Ethics 
Review Board of the Institute for Maternal and Child 
Health ‑ IRCCS ‘Burlo Garofolo’ (Trieste, Italy) provided 
approval of the study (n.185/08, 19/08/2008). For a child 
to be eligible, informed consent was required from the 
parents or guardians. For ethical reasons, the study popula-
tion of pediatric patients was restricted to those who were 
undergoing a medically indicated peripheral venous blood 
sampling prior to elective surgical interventions or within 
the scope of elective diagnostic procedures. Furthermore, 
for the control group, subjects were excluded from the 
study if they had an acute or chronic infectious disease, 
any clinically significant disorder, or if they were on any 
medication with a known effect on immunological factors, 
such as corticosteroids. Blood samples were collected from 
the control subjects (CTRL, n=37) and IBD patients (IBD, 
n=26). The clinical characteristics of the subjects included 
in the study are shown in Table I. Patient history, with regard 
to breast‑feeding, vaccinations, previous infectious diseases 
and allergy, was documented but not evaluated as covariates 
in the study, since subgroup analysis required a larger popu-
lation size.
Determination of the cytokine and chemokine levels. The 
investigated panel comprised 48 cytokines or chemokines 
known to or hypothesized to be involved in inflammatory 
processes. The panel included interleukin (IL)‑receptor 
antagonist (RA), IL‑1β, IL‑2, IL‑4, IL‑5, IL‑6, IL‑7, IL‑8, 
IL‑9, IL‑10, IL‑12 (p70), IL‑13, IL‑15, IL‑17, eotaxin, 
fibroblast growth factor (FGF)‑basic, granulocyte‑colony 
stimulating factor (G‑CSF), granulocyte‑macrophage 
colony‑stimulating factor (GM‑CSF), interferon (IFN)‑γ, 
IFN‑γ‑inducible protein (IP)‑10, monocyte chemoattrac-
tant protein (MCP)‑1, macrophage inflammatory protein 
(MIP)‑1α, platelet‑derived growth factor (PDGF)‑BB, 
MIP-1β, regulated on activation, normal T cell expressed 
and secreted (RANTES), tumor necrosis factor (TNF)‑α, 
vascular endothelial growth factor (VEGF), IL‑1α, IL-2Rα, 
IL‑3, IL‑12 (p40), IL‑16, IL‑18, cutaneous T‑cell‑attracting 
chemokine (CTACK), growth regulated oncogene (GRO)-α, 
hepatocyte growth factor (HGF), IFN‑α2, leukemia inhibi-
tory factor (LIF), MCP‑3, macrophage colony‑stimulating 
factor (M‑CSF), macrophage migration inhibitory factor 
(MIF), monokine induced by γ‑IFN (MIG), β‑nerve growth 
factor (NGF), stem cell factor (SCF), stem cell growth factor 
(SCGF)‑β, stromal cell‑derived factor (SDF)‑1α, TNF‑β and 
TNF‑related apoptosis‑inducing ligand (TRAIL). Analysis of 
the panel was performed with the collected serum samples, 
using a magnetic bead‑based multiplex immunoassay 
(Bio‑Plex®; Bio‑Rad Laboratories, Inc., Milan, Italy), as 
previously described (11‑13). Experiments were performed 
according to the manufacturer's instructions. Data from 
the reactions were acquired using a Bio‑Plex® 200 reader 
(Bio‑Rad Laboratories, Inc.), while a digital processor 
(Toshiba Intel® Celeron® CPU B820; Toshiba, Tokyo, Japan) 
was used to manage the data output. Application of Bio‑Plex 
Manager® software (Bio‑Rad Laboratories, Inc.) enabled 
presentation of the data as the median fluorescence intensity 
and concentration (pg/ml).
Statistical analysis. For each set of experiments, the cytokine 
levels are presented as the median values with the interquar-
tile range. To compare the differences between the values 
in the two distinct groups, a non‑parametric Mann‑Whitney 
rank‑sum test was applied, where P≤0.05 was considered to 
indicate a statistically significant difference. In the case of 
multiple comparisons, the Bonferroni correction was applied, 
where 0.05 was divided by the number of multiple compari-
sons. Analyses were performed using GraphPad Prism 5.0 
software (GraphPad Software, Inc., La Jolla, CA, USA) and 
Stata/IC 11.2 software (StataCorp LP, College Station, TX, 
USA).
Results
Pediatric IBD patients exhibit a distinct cytokine profile 
when compared with the normal controls, with 10 cyto-
kines/chemokines exhibiting significantly higher values in 
IBD patients. All the serum concentrations of cytokines and 
chemokines, acquired following the magnetic bead‑based 
multiplex immunoassay, in the pediatric IBD patients and 
controls are reported in Table II. Among the 48 investigated 
cytokines and chemokines, eight cytokines/chemokines were 
not detectable in the sera of the controls or IBD pediatric 
patients, which included IL‑15, GM‑CSF, IL‑1α, IL‑3, IL‑12 
(p40), MCP‑3, β‑NGF and TNF‑β. The majority of cyto-
kines and chemokines (n=27) did not exhibit a statistically 
significant difference when comparing the values in the IBD 
and CTRL groups. These cytokines and chemokines were 
IL‑1RA, IL‑4, IL‑6, IL‑8, IL‑9, IL‑10, IL‑12 (p70), IL‑13, 
eotaxin, FGF‑basic, G‑CSF, MCP‑1, MIP‑1α, PDGF‑BB, 
RANTES, TNF‑α, VEGF, IL‑2Rα, IL‑18, GRO‑α, HGF, 
M‑CSF, MIF, SCF, SCGF‑β, SDF‑1α and TRAIL. However, 
10 cytokines/chemokines exhibited significantly higher 
concentrations (P<0.05) in the IBD patients when compared 
with the CTRL group. These cytokines and chemokines 
Table I. Profile of the controls and the patients with IBD.
Group Cases (n) Age (years)a Gender, M/F (n) Pathology
Controls 37 11 (1/17) 15/22 ‑
IBD 26   9 (1/16) 14/12  Crohn's disease (n=15)
    Ulcerative colitis (n=11)
aResults are expressed as the median (minimum/maximum). M, male; F, female; IBD, inflammatory bowel disease.
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Table II. Concentrations of cytokines and chemokines in the patients with IBD and the healthy controls.
Cyto/chemokine Controls IBD
IL-1β nd 3.21 (nd‑7.09)a
IL‑1RA 160 (133.7‑193) 239.3 (139‑370.9)
IL‑2 12.86 (9.93‑16) 4.33 (1.31‑12.62)a
IL‑4 8.01 (7.75‑8.7) 10.29 (5.54‑16.14)
IL‑5 nd 3.31 (nd‑6.97)a
IL‑6 12.3 (10.41‑15.22) 18.16 (11.2‑30.9)
IL‑7 11.1 (2.29‑14.97) 31.17 (13.15‑49.76)a
IL‑8 32.28 (28.74‑38.29) 38.57 (24.67‑64.12)
IL‑9 23.5 (16.38‑29.81) 21.34 (12.93‑33.6)
IL‑10 9.35 (nd‑11.43) 5.29 (nd‑16.54)
IL‑12 (p70) 40.5 (23.61‑50.38) 17.73 (10.38‑43.35)
IL‑13 9.36 (7.97‑11.68) 4.26 (1.52‑8.13)
IL‑15 nd nd
IL‑17 111 (98.37‑132.5) 44.59 (15.46‑99.85)a
Eotaxin 11.73 (nd‑46.26) 42.52 (nd‑171.8)
FGF‑basic 38.6 (33.23‑49.16) 35.07 (19.55‑59.91)
G‑CSF 43.97 (34.28‑53.47) 52.88 (35.79‑93.16)
GM‑CSF nd nd
IFN‑γ 163.8 (147.1‑177.4) 1105 (238‑2412)a
IP‑10 542.5 (390.2‑872.6) 3486 (576.3‑6348)a
MCP‑1 50.78 (26.87‑77.01) 23.37 (13.37‑45.71)
MIP-1α 7.02 (6‑8.02) 5.84 (3.48‑8.23)
PDGF‑BB 8479 (6714‑10519) 5182 (3387‑11838)
MIP-1β 99.38 (79.2‑131.7) 52.59 (35.96‑72.8)a
RANTES 4633 (nd‑5457) 1592 (nd‑17660)
TNF‑α 30.44 (23.81‑36.31) 38.82 (23‑55.57)
VEGF 82.2 (46.72‑124.9) 91.71 (54.33‑209.2)
IL-1α nd nd
IL-2Rα 145.4 (76.49‑199.7) 173.6 (68‑338.5)
IL‑3 nd nd
IL‑12 (p40) nd nd
IL‑16 144 (83.92‑195.8) 473.4 (164.3‑1343)a
IL‑18 196 (102.1‑284.4) 120.6 (74.95‑180.5)
CTACK 406 (259.3‑527.8) 716.2 (548.6‑889.3)a
GRO‑α 11.6 (78.63‑195.9) 158.3 (58.62‑250.6)
HGF 404.2 (290.3‑555.5) 382.1 (279.1‑513.5)
IFN‑α2 nd 54.05 (30.27‑74.11)a
LIF nd nd (nd‑12.09)a
MCP‑3 nd nd
M‑CSF 8.02 (nd‑13.22) nd (nd‑15.05)
MIF 393.5 (73.17‑3127) 3731 (572.1‑7002)
MIG 393 (228.3‑676) 2523 (1141‑3821)a
β‑NGF nd nd
SCF 1048 (113‑1514) 135.5 (64.75‑233.3)
SCGF‑β 36615 (22073‑73267) 39607 (22791‑60520)
SDF‑1α 37.46 (17.34‑75.02) 47.59 (nd‑352.3)
TNF‑β nd nd
TRAIL 85.28 (49.52‑104.9) 71.41 (49.84‑118.4)
Values are expressed as the median (interquartile range) in pg/ml. aP<0.05, vs. control group (Mann‑Whitney test with Bonferroni correction for 
multiple comparisons). nd, non‑detectable; IBD, inflammatory bowel disease; IL, interleukin; IL‑1RA, interleukin‑1 receptor antagonist; FGF, 
fibroblast growth factor; G‑CSF, granulocyte‑colony stimulating factor; GM‑CSF, granulocyte‑macrophage colony‑stimulating factor; IFN, inter-
feron; IP, IFN‑γ‑inducible protein; MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory protein; PDGF, platelet‑derived growth 
factor; RANTES, regulated on activation, normal T cell expressed and secreted; TNF, tumor necrosis factor; VEGF, vascular endothelial growth 
factor; CTACK, cutaneous T‑cell‑attracting chemokine; GRO, growth regulated oncogene; HGF, hepatocyte growth factor; LIF, leukemia inhibitory 
factor; M‑CSF, macrophage colony‑stimulating factor; MIF, macrophage migration inhibitory factor; MIG, monokine induced by γ‑IFN; NGF, nerve 
growth factor; SCF, stem cell factor; SCGF, stem cell growth factor; SDF, stromal cell‑derived factor; TRAIL, TNF‑related apoptosis‑inducing 
ligand.
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Figure 1. Box plots showing the serum levels (pg/ml) of IL‑1β, IL‑5, IL‑7, IFN‑γ, IP‑10, IL‑16, CTACK, IFN‑α2, LIF and MIG in the CTRL (gray) and IBD 
(white) groups. Whiskers were calculated using the Tukey method and outliers are not shown. *P<0.05, vs. CTRL group (Mann‑Whitney test with Bonferroni 
correction for multiple comparisons). IL, interleukin; IFN, interferon; IP, IFN‑γ‑inducible protein; CTACK, cutaneous T‑cell‑attracting chemokine; LIF, 
leukemia inhibitiory factor; MIG, monokine induced by γ‑IFN; CTRL, control; IBD, inflammatory bowel disease.
Figure 2. Box plots showing the serum levels (pg/ml) of IL‑2, IL‑17 and MIP‑1β in the CTRL (gray) and IBD (white) groups. Whiskers were calculated using 
the Tukey method and outliers are not shown. *P<0.05, vs. CTRL (Mann‑Whitney test with Bonferroni correction for multiple comparisons). IL, interleukin; 
MIP, macrophage inflammatory protein; CTRL, control; IBD, inflammatory bowel disease.
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included IL‑1β, IL‑5, IL‑7, IFN‑α2, IFN‑γ, IP‑10, CTACK, 
IL‑16, LIF and MIG (Fig. 1).
Levels of certain circulating cytokines are significantly 
decreased in pediatric IBD patients when compared with the 
normal controls. The majority of cytokines and chemokines 
were unaffected or significantly (P<0.05) increased in the 
pediatric IBD patients when compared with the age‑matched 
control subjects. However, it is particularly notable that two 
cytokines, IL‑2 and IL‑17, and one chemokine, MIP‑1β, 
exhibited significantly decreased levels in the pediatric 
IBD patients when compared with the age‑matched controls 
(Fig. 2).
Discussion
The presence of deregulated cytokines and chemokines has 
been previously reported in cases of IBD, primarily in studies 
performed at the level of the inflamed mucosa, while studies 
on the circulating levels of cytokines and chemokines in IBD 
are less frequent (14‑17). Among the panel of cytokines and 
chemokines investigated in the present study, 10 proteins, 
including IL‑1β, IL‑5, IL‑7, IFN‑α2, IFN‑γ, IP‑10, CTACK, 
IL‑16, MIG and LIF, were shown to be significantly upregu-
lated in the group of pediatric IBD patients, as compared with 
the age‑matched controls. While a number of these molecules, 
including IL‑1β, IP‑10 and IL‑16 in particular, are known 
to have a strong proinflammatory activity (18‑24), certain 
other molecules, such as IFNs, may account for compensa-
tory mechanisms aimed at decreasing the inflammatory 
status (25).
However, the most notable finding of the present study 
was that a small number of cytokines and chemokines were 
significantly downregulated in the serum of the IBD pedi-
atric patients when compared with the age‑matched healthy 
controls. These data are completely novel and unexpected, 
particularly considering that in IBD patients, concentrations 
of MIP‑1β, IL‑2 and IL‑17 (26‑30) have been previously 
reported to be upregulated at the mucosal level. The data 
concerning IL‑17 are particularly significant, since IL‑17 has 
been proposed as a potential therapeutic target for IBD (31). 
In addition, the results may aid the interpretation of certain 
paradoxical effects resulting from anti‑TNF therapy that 
have been observed in IBD patients, such as the occurrence 
of psoriasis in a subset of IBD patients (32). Therefore, the 
results demonstrate, in accordance with the observations of 
a previous study (33), that the role of IL‑17 in the physiopa-
thology of IBD is complex. 
In conclusion, the results of the present study indicate that 
the immunological characteristics of IBD are more complex 
than originally hypothesized, and may comprise certain aspects 
of immune‑deficiency. To date, the precise balance between 
proinflammatory and antiinflammatory cytokines/chemokines 
during the progression of IBD remains unknown. The correct 
evaluation of cytokines and chemokines involved in the prog-
ress of the disease is crucial for identifying potential novel 
targets for drug treatments.
Further studies are necessary to improve the understanding 
of IBD etiology and to clarify whether there are differences 
between Crohn's disease and ulcerative colitis. Other param-
eters to be considered include genetic background, disease 
onset, the age of the patients and pharmacological treat-
ment (34,35).
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